Captopril inhibits peptidylglycine-α-hydroxylating monooxygenase: Implications for therapeutic effects

Pharmacology

Volumn 58, Issue 5, 1999, Pages 270-280

  Mueller, S Alyssa ^a   Driscoll, William J ^a   Mueller, Gregory P ^a  

^a Uniformed Services University of the Health Sciences   (United States)

Author keywords

Angiotension converting enzyme inhibitors; Captopril; Copper; Peptides; Peptidylglycine hydroxylating monooxygenase; Sulfhydryl; amidation

Indexed keywords

ALPHA AMIDATING ENZYME; CAPTOPRIL; COPPER ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032945118     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028290     Document Type: Article

References (17)

1. Herman AG: Differences in the structure of angiotensin-converting enzyme inhibitors might predict differences in action. Am J Cardiol 1992;70:102C-108C.
2. Bernstein KE, Martin BM, Edwards AS, Bernstein EA: Mouse angiotensin-converting enzyme is a protein composed of two homologous domains. Proc Natl Acad Sci USA 1989;264:11945-11951.
3. Cushman DP, Cheung HS, Sabo EF, Ondetti MA: Angiotensin converting enzyme inhibitors: Evolution of a new class of antihypertensive drugs; in Horovitz ZP (ed): Angiotensin Converting Enzyme Inhibitors: Mechanisms of Action and Clinical Implications. München, Urban & Schwarzenberg, 1981, pp 3-25.
4. Palatini P, Dabbeni-Sala F, Finotti P: Inhibition of dopamine β-hydroxylase by captopril. Biochem Pharmacol 1989;38:1011-1013.
5. Eipper BA, Stoffer DA, Mains RE: The biosynthesis of neuropeptides: Peptide α-amidation. Annu Rev Neurosci 1992;15:57-85.
6. Jackson EK, Garrison JC: Renin and angiotensin; in Hardman JL, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds): The Pharmacological Basis of Therapeutics, ed 9. New York, McGraw-Hill, 1996, pp 733-751.
7. Duchin KL, McKinstry DN, Cohen AI, Migdalof BH: Pharmacokinetics of captopril in healthy subjects and in patients with cadiovascular disease. Clin Pharmacokinet 1988;14: 241-259.
8. Kolhekar AS, Keutmann HT, Mains RE, Quon AS, Eipper BA: Peptidylglycine α-hydroxylating monooxygenase: Active site residues, disulfide linkages, and a two-domain model of the catalytic core. Biochemistry 1997;36:10901-10909.
9. Perkins S, Husten EJ, Eipper BA: The 108-kDa peptidylglycine α-amidating monooxygenase precursor contains two separable enzymatic activities involved in peptide amidation. Biochem Biophys Res Commun 1990;171:926-932.
10. Piszkiewicz D: Kinetics of Chemical and Enzyme-Catalyzed Reactions. New York, Oxford University Press, 1977, pp 91-97.
11. Mueller GP, Husten EJ, Mains RE, Eipper BA: Peptide α-amidation and peptidylglycine α-hydroxylating monooxygenase: Control by disulfiram. Mol Pharmacol 1994;44:972-980.
12. Nagatsu T, Kuzuya H, Hidaka H: Inhibition of dopamine β-hydroxylase by sulfhydryl compounds and the nature of the natural inhibitors. Biochim Biophys Acta 1967;139: 319-327.
13. Erion MD, Tan J, Jeng AY: Inhibition of peptidylglycine α-amidating monooxygenase by N-substituted homocysteine analogs. J Med Chem 1994;37:4430-4437.
14. Unger T, Ganten D, Lang RE, Scholkens BA: Persistent tissue converting enzyme inhibition following chronic treatment with Hoe98 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985;7:36-41.
15. Cohen ML, Kurz KD: Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1982;220:63-69.
16. Nash DT: Comparative properties of angiotensin-converting enzyme inhibitors: Relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications. Am J Cardiol 1992;67:26C-32C.
17. Southan C, Kruse LI: Sequence similarity between dopamine β-hydroxylase and peptide α-amidating enzyme: Evidence for a conserved catalytic domain. FEBS Lett 1989;255: 116-120.